Agios Pharmaceuticals (AGIO) Total Non-Current Liabilities (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 11 years of Total Non-Current Liabilities data on file, last reported at $82.2 million in Q2 2026.

• Quarterly Total Non-Current Liabilities fell 19.12% year-over-year to $82.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $82.2 million (down 19.12% YoY) and the FY2025 annual result came in at $104.0 million, down 14.29% from the prior year.
• Total Non-Current Liabilities grew to $82.2 million in Q2 2026, from $75.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $164.0 million in Q3 2024 to a low of $75.8 million in Q1 2026.
• A 5-year average of $113.1 million and a median of $113.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 37.49% — and 2025, when it plunged 38.23%.
• Tracing AGIO's Total Non-Current Liabilities over 5 years: stood at $134.6 million in 2022, then dropped by 7.19% to $124.9 million in 2023, then declined by 2.87% to $121.4 million in 2024, then decreased by 14.29% to $104.0 million in 2025, then declined by 21.01% to $82.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $82.2 million (Q2 2026), $75.8 million (Q1 2026), and $104.0 million (Q4 2025), per Business Quant data.